
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. demonstrates a solid financial outlook, highlighted by its robust performance in the U.S. spine market, which outpaced overall market growth and contributed to a significant 10% revenue increase in the fourth quarter. The company benefits from a strong free cash flow trajectory, boasting an impressive 8% free cash flow yield while trading below historical valuation levels, indicating potential for upside. Additionally, the enabling technology segment has achieved its highest revenue to date, showcasing effective operational execution and enhanced growth prospects for the future.
Bears say
The financial outlook for Globus Medical Inc. presents several downside risks that contribute to a negative perspective on its stock. Key concerns include potential disruptions from the NUVA and NVRO mergers, alongside a deceleration in growth within the spine end market due to possible changes in reimbursement and pricing pressures. Additionally, the competitive landscape may intensify with new entrants gaining focus in the spine market, while underperforming product launches and slower growth in new musculoskeletal areas could further impact the company’s revenue trajectory and operating margins.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares